A Whale Investor Shorting SK Hynix has Lost More Than the Initial Investment, with an Unrealized Loss of $1.6 million
BlockBeats News, May 11, according to Hyperinsight monitoring, a stock price has been rising recently. On Hyperliquid, whales with a million-dollar or larger position in a futures contract are all in short positions, currently all facing unrealized losses.
The whale with the deepest unrealized loss opened a short position on February 20 with 4x leverage, shorting 3394.6 futures contracts (equivalent to about $4.36 million), with an entry price of $816 and a liquidation price of $1592. After holding the position for nearly 3 months, the current unrealized loss has expanded to $1.58 million, a loss percentage of 119%, equivalent to more than double the initial investment. As of the time of writing, the position has not been closed.
At a historical high for the asset, the contract on Hyperliquid is currently trading at $1299. New short positions are still being entered, with the most recent whale entering at an average price of $1250; the closest short address to liquidation on-chain is at $1451.
Address: 0xa55e490ab10f1e90b288a5f69c96f9e47547ae2e
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD
Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.
TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).
Crypto prices
More
